James M. Kirshenbaum, MD, FACC
|
|
- Harold Gibbs
- 5 years ago
- Views:
Transcription
1 James M. Kirshenbaum, MD, FACC Associate Professor of Medicine Harvard Medical School Co-Director, Clinical Cardiology Director, Acute Interventional Cardiology Brigham and Women s Hospital Boston, MA Source (Photos): Davies MJ Heart 83:361,2000 Risk Reduction of Ischemic Events Objective Reduce the risk of recurrent cardiovascular events and/or mortality Control of risk factors to goal Smoking (cessation) Hyperlipidemia (LDL <70) Hypertension (BP <130/85) Diabetes (Hgb A1c <7) Diet/exercise/life style Pharmacologic therapy ASA Clopidogrel (post ACS/stent) ACE/ARB Beta-blocker Statin Treatment of Symptoms Objective Reduce symptoms to increase exercise tolerance, and functional capacity Anti-ischemic therapy Beta-blockers Nitrates Calcium antagonists Ranolazine Revascularization PCI or CABG 1
2 (<24hrs) (Discharge) 1. ASA 2. Clopidogrel/Prasugrel 3. Heparin/LMWH 4. Direct Thrombin Inhibitors 5. GP IIb/IIIa inhibitors 6. Factor Xa antagonists 7. Beta-blockers 8. Nitrates Libby P. Circ 2001;104:365, 1. ASA 2. Clopidogrel 3. Beta-blockers 4. ACE Inhibitors 5. Statins 6. Risk factor + Lifestyle Δ s 2007 ACC/AHA UA/NSTEMI Guideline Revision! Secondary Prevention BP control <140/90 mm Hg <130/80 mm Hg with diabetes or CKD Diabetes management: HbA 1c <7% Smoking cessation/no environmental smoke exposure Education, referral programs, drug therapy Physical activity (30-60 min, 7 d/wk; min 5 d/wk) Weight management BMI kg/m 2 Waist circumference: men, <40 in; women, <35 in Discharge education/referral Stepped-care approach to musculoskeletal pain management Annual influenza immunization HRT, antioxidant vitamin supplements (C, E, beta carotene) and folic acid not recommended Anderson JL, et al. J Am Coll Cardiol. 2007;50: ACIP: Study design Angiographic CAD ( 50% stenosis in 1 major vessel or branch) suitable for revascularization + ischemia during exercise or pharmacologic stress testing and 1 asymptomatic episode during 48-hr AECG Angina-guided strategy (n = 183) Ischemia-guided strategy (n = 183) Revascularization strategy (n = 192) Primary outcome: Absence of ischemia at 12 weeks Secondary outcomes: Death, MI, recurrent hospitalization for cardiac disease, nonprotocol revascularization at 1 and 2 years Asymptomatic Cardiac Ischemia Pilot Pepine CJ et al. J Am Coll Cardiol. 1994:24:1-10. Davies RF et al. Circulation. 1997;95:
3 ACIP: Two-year cumulative rates of death, MI, or cardiac hospitalization Davies, R. F. et al. Circulation 1997;95: Copyright 1997 American Heart Association ACIP: Two-year cumulative all-cause mortality rates for the treatment strategies 8 6.6% Angina guided Percent % Ischemia guided 1.1% Revascularization P = 0.34 P < 0.05 P < Follow-up (months) 24 Davies RF et al. Circulation. 1997;95: SWISSI II: Study design Recent first MI with asymptomatic myocardial ischemia on exercise testing and 1- or 2-vessel coronary disease suitable for PCI PCI (n = 96) Randomized, unblinded Anti-ischemic therapy* (n = 105) Primary outcomes: Cardiac death, nonfatal MI, symptom-driven revascularization Follow-up: 10.2 years (mean) *Nitrates, β-blockers, CCBs All patients also received aspirin and statin Swiss Interventional Study on Silent Ischemia Type II Erne P et al. JAMA. 2007;297:
4 SWISSI II: Treatment effect on primary outcome Cardiac death, nonfatal MI, symptom-driven revascularization No. at risk PCI Anti-ischemic drug therapy *Log-rank Event-free survival PCI Drug therapy P < 0.001* Time from randomization (years) Erne P et al. JAMA. 2007;297: ACIP, SWISSI II: Summary and implications ACIP: In patients with documented CAD + symptomatic and asymptomatic ischemia, PCI compared with antiischemic or antianginal therapy reduced 2-year risk of major CV events SWISSI II extended these finding to post-mi patients with asymptomatic ischemia and a longer 10-year follow-up Davies RF et al. Circulation. 1997;95: Erne P et al. JAMA. 2007;297: Patient expectations about elective PCI for stable CAD N = 52 consecutive patients scheduled for first elective PCI; semi-structured questionnaire completed prospectively Do you think the angioplasty will prevent a heart attack? Yes 75% Do you think the angioplasty will help you live longer? Yes 71% Holmboe ES et al. J Gen Intern Med. 2000;15:
5 Perceived benefit of PTCA for coronary disease Rothberg. Ann Intern Med 2010;153:307 Conventional Wisdom Treatment Assumptions in CAD Management: Patients with symptomatic CAD and chronic angina who have significant coronary stenoses need revascularization Revascularization is required to improve prognosis PCI is less invasive than CABG surgery (i.e., is safer) and, therefore, should be selected Effects of Medical vs PCI Therapy on Angina Symptoms in Stable CAD 1018 stable CAD patients: 504 randomized to PTCA, 514 randomized to medical treatment Followup: 2.7 years Difference in Angina Class > II; Medical PTCA, 95% CI P<0.001 Angina better managed with PTCA, but difference attenuated over time (related to revasc in med group) (RITA-2 trial participants. Lancet 1997;350:461) 5
6 Effects of Medical vs PCI Therapy on ETT Performance in Stable CAD RITA-2, 1018 patients (504 PTCA, 514 medical management) ETT duration better in pts with PTCA, but difference attenuated over time (related to subsequent revascularization in medical group) (RITA-2 trial participants. Lancet 1997;350:461) Longterm Outcome in PCI vs Medical Management in RITA-2 RITA-2, 1018 patients (504 PTCA, 514 medical management) Death Death or MI P=NS P=NS No difference in outcome over median of 7 years (Henderson, et al. JACC 2003;42:1161) Effect of Medical Therapy vs. PTCA vs. CABG for Multivessel CAD (MASS-II) Multivessel CAD with obstruction > 70% Stable angina CCS II or III Baseline management: Beta blockers, Ca ++ blockers, nitrates, ACE, statins, ASA Randomization (n=611 patients): Ongoing medical management 203 patients PCI (bare metal stents) 205 patients CABG (92% with LIMA) 203 patients Medical management continued in all groups Minimal followup 1 year (Hueb, et al. JACC 2004;43:1743) 6
7 Effect of Medical Therapy vs. PTCA vs. CABG for Multivessel CAD (MASS-II) Persisting Anginal Symptoms at One Year P= % with Persisting Angina P=0.16 (Hueb, et al. JACC 2004;43:1743; Favarato, et al Circ 2003;108:II-21) Effect of Medical Therapy vs. PTCA vs. CABG for Multivessel CAD (MASS-II) Freedom from additional revascularization within first year P= (Hueb, et al. JACC 2004;43:1743) Effect of Medical Therapy vs. PTCA vs. CABG for Multivessel CAD (MASS-II) Incidence of cardiac mortality P=NS No difference in cardiac mortality (Hueb, et al. JACC 2004;43:1743) 7
8 Survival Curves from Major Randomized Clinical Trials Comparing Medical vs Surgical Therapy of CAD (Eager, et al. ACC/AHA guidelines for CABG JACC 1999;34:1262) Stable CAD: PCI vs Conservative Medical Management Meta-analysis of 11 randomized trials; N = 2,950 Favors Favors Medical PCI Management Death Cardiac death or MI Nonfatal MI CABG PCI Risk ratio Katritsis DG et al. Circulation. 2005;111: (95% Cl) P Background More than 1 million PCI procedures are performed in the U.S. annually, the great majority of which are undertaken electively in patients with stable CAD Although successful PCI of flow-limiting stenoses might be expected to reduce the rate of death, MI or hospitalization for ACS, prior studies have shown only that PCI decreases the frequency of angina and improves short-term exercise performance 8
9 COURAGE: Defining optimal care Clinical Outcomes Utilizing Revascularization and Aggressive Guideline-Driven Drug Evaluation Intensive lifestyle intervention Reduce symptoms Treat underlying disease Intensive medical therapy Revascularization? Hypothesis PCI + Optimal Medical Therapy will be Superior to Optimal Medical Therapy Alone COURAGE: Study design AHA/ACC Class I/II indications for PCI, suitable coronary artery anatomy + 70% stenosis in 1 proximal epicardial vessel + objective evidence of ischemia (or 80% stenosis + CCS class III angina without provocation testing) Optimal medical therapy* + PCI (n = 1149) Randomized Optimal medical therapy* (n = 1138) Primary outcomes: All-cause mortality, nonfatal MI Secondary outcomes: Death, MI, stroke; ACS hospitalization Follow-up: Median 4.6 years *Intensive pharmacologic therapy + lifestyle intervention CCS = Canadian Cardiovascular Society Boden WE et al. Am Heart J. 2006;151: Boden WE et al. N Engl J Med. 2007;356:
10 COURAGE: Pharmacologic therapy Antiplatelet Aspirin Clopidogrel in accordance with established practice standards Dyslipidemia Simvastatin ± ezetimibe, ER niacin, or fibrates β-blocker ER metoprolol Calcium channel blocker Amlodipine Nitrate Isosorbide 5-mononitrate ACEI, ARB, or diuretic Lisinopril or losartan Boden WE et al. Am Heart J. 2006;151: Boden WE et al. N Engl J Med. 2007;356: COURAGE: Lifestyle intervention and risk factor goals Smoking cessation Exercise program 30 min moderately intensive exercise 5x/week Nutrition counseling Total dietary fat <30% of calories Saturated fat <7% of calories Dietary cholesterol <200 mg/day Weight control BMI <25 kg/m 2 (if baseline BMI ) 10% relative weight loss (if baseline BMI >27.5) LDL-C (mg/dl) HDL-C (mg/dl) 40 Triglycerides (mg/dl) <150 BP (mm Hg) <130/85 <130/80 if diabetes or renal disease present A1C (%) <7.0 Boden WE et al. Am Heart J. 2006;151: COURAGE: Treatment effect on primary outcome All-cause death, MI Survival free of primary outcome Years Medical therapy No. at risk Medical therapy PCI HR 1.05 ( ) P = 0.62* PCI + medical therapy *Unadjusted, log-rank Boden WE et al. N Engl J Med. 2007;356:
11 Value of Optimal Medical Therapy: The COURAGE Trial Compared with Optimal Medical Therapy alone, PCI provided no incremental benefit on Death, MI, New ACS Death/MI Death New ACS New MI (Boden, et al. NEJM 2007;356:1503) Value of Optimal Medical Therapy: The COURAGE Trial Compared with Optimal Medical Therapy alone, PCI is associated with a reduction in angina, but not after 5 yrs pns 87 PCI + Optimal Rx Optimal Rx alone 75 Percent With Angina 50 P< P= pns Baseline 1 Year 3 Year 5 Year (Boden, et al. NEJM 2007;356:1503) COURAGE: Treatment effect in CV and diabetes subgroups Baseline characteristics Myocardial infarction Yes No Extent of CAD Multivessel disease Single-vessel disease Diabetes Yes No Angina CCS 0-I CCS II-III Ejection fraction 50% >50% Previous CABG No Yes PCI better Medical therapy better Hazard ratio (95% CI) Boden WE et al. N Engl J Med. 2007;356:
12 COURAGE QOL & Health Status Findings: 14 Aug Freedom from Angina During Follow-up & NNT to Improve Sx Characteristic: CCS Class 0 PCI + OMT OMT NNT to improve angina in 1 pt with PCI CLINICAL Angina free no. Baseline 12% 13% Yr *66% 58% Yr *72% 67% 20 5 Yr 74% 72% 50 * The comparison between the PCI group and the medical-therapy group was significant at 1 year ( P<0.001) and 3 years (P=0.02) but not at baseline or 5 years. Weintraub. NEJM 2008;359:677 Quality of Life Improvement with PCI? Weintraub. NEJM 2008;359:677 12
13 BARI 2D: Enrollment and Randomization The BARI 2D Study Group. N Engl J Med 2009;360: BARI 2D Trial design: Patients with type 2 diabetes and coronary artery disease were randomized (2x2 factorial design) to revascularization (n = 953) versus medical therapy (n = 991) and to insulin-sensitization (n = 977) versus insulin-provision (n = 967). Follow-up 5.3 years. % p = 0.97 p = Results Mortality: 11.7% with revasc vs. 12.2% with medical therapy (p = 0.97); 11.8% with insulinsensitization vs. 12.1% with insulin-provision (p = 0.89) PCI stratum, MACE: 23.0% with revasc vs. 21.1% with medical therapy (p = 0.15) CABG stratum, MACE: 22.4% with revasc vs. 30.5% with medical therapy (p = 0.01) Mortality Revascularization Medical therapy Mortality Insulinsensitization! Insulin-provision! Conclusions Among patients with diabetes and stable coronary artery disease, revascularization by PCI or CABG failed to demonstrate superiority to medical therapy at 5.3 years There was also no notable benefit from insulin-sensitizing therapy versus insulinproviding therapy BARI 2D Study Group. N Engl J Med 2009; 360: BARI 2D: Rates of Survival and Freedom from Major Cardiovascular Events, According to PCI and CABG Strata The BARI 2D Study Group. N Engl J Med 2009;360:
14 Hachamovitch, R. et al. Circulation 2003;107: Observed cardiac death rates over the follow-up period in patients undergoing revascularization (Revasc) vs medical therapy (Medical Rx) as a function of the amount of inducible ischemia Hachamovitch, R. et al. Circulation 2003;107:
15 Mortality hazard for (Revasc) vs medical therapy (Medical Rx) as a function of % ischemic myocardium in 10,627 consecutive pts. Followed for 1.9 +/- 0.6 yrs Circulation 2008;117: Hypothesis: Reduction in Ischemia will be greater for patients Randomized to PCI+OMT than for those Randomized to OMT Source: Shaw et al. J Nucl Cardiol 2006;13:
16 33.3% with > 5% ischemia reduction 18.9% with > 5% ischemia reduction Shaw et al. J Nucl Cardiol 2006;13: Shaw LJ Circulation. 2008;117:1283. Shaw LJ Circulation. 2008;117:
17 Shaw LJ Circulation. 2008;117:1283 Conclusions PCI as an initial management strategy in the setting of stable CAD has not been shown to reduce the incidence of Death or MI PCI has not been shown to prolong life expectancy PCI added to OMT was more effective in reducing ischemia and improving angina than OMT, particularly in patients with moderate-to-severe prerx ischemia Most patients will have improvement in anginal status whether treated initially with PCI+OMT or OMT alone Peterson NEJM 2008;359:7 Controversies remain Patients randomized after coronary angiograms preformed Patients excluded with severe LV dysfunction, clinical instability, or very early ST-segment depression or hypotension 33% of patients in medical group crossed over to revascularization 17
18 Medical Therapy vs PCI + Medical Therapy For Stable CAD Nishilgaki: J Am Coll Cardiol Intv 2008;1:469 Medical Therapy vs PCI + Medical Therapy For Stable CAD Nishilgaki: J Am Coll Cardiol Intv 2008;1:469 Summary Among patients with CAD, ample data indicate a direct relationship between the presence and magnitude of ischemia and the likelihood of death and MI. This relationship appears to be independent of the degree of symptoms. Revascularization coupled with medical therapy is more effective in relieving ischemia than medical therapy alone Whether routinely applied revascularization, as an adjunct to medical therapy, reduces the incidence of death or MI among CAD patients with significant ischemia remains unknown. 18
19 Questions to answered next: Among stable patients with moderate-tosevere provokable cardiac ischemia and preserved cardiac function would an initial strategy of cardiac catheterization followed by revascularization (PCI or CABG) and OMT be superior to a strategy of OMT alone for reducing the incidence of death or MI. Pharmacologic vs Revascularization Therapy for Stable CAD Critical Caveats in Interpreting Studies Field of PCI very rapidly evolving, with dramatic improvements in preventing restenosis: Balloon angioplasty (PTCA) Bare metal stents (BMS) Drug eluting stents (DES) Newer stent platforms Field of pharmacologic vascular protection and plaque stabilization also very rapidly evolving with dramatic improvements in medical outcomes A Comprehensive Approach to Managing Obstructive Coronary Artery Disease! Revascularization to relieve symptoms 19
2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationThe Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina
The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina Ajay J. Kirtane,, MD Columbia University Medical Center The Cardiovascular Research Foundation Conflict of Interest
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationManagement of stable CAD FFR guided therapy: the new gold standard
Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients
More informationEvaluating Clinical Risk and Guiding management with SPECT Imaging
Evaluating Clinical Risk and Guiding management with SPECT Imaging Raffaele Giubbini Chair and Nuclear Medicine Unit University & Spedali Civili Brescia- Italy U.S. Congressional Budget Office. Technological
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationTrial. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
Trial International Study of Comparative Health Effectiveness with Medical and Invasive Approaches Stable Ischemic Heart Disease What is the best initial management strategy for patients with SIHD? What
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationScreening for Asymptomatic Coronary Artery Disease: When, How, and Why?
Screening for Asymptomatic Coronary Artery Disease: When, How, and Why? Joseph S. Terlato, MD FACC Clinical Assistant Professor, Brown Medical School Coastal Medical Definition The presence of objective
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationCOURAGE to Leave Diseased Arteries Alone
COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationMaster Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationDECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators
DECISION - CTO Drug-Eluting stent Implantation versus optimal Medical Treatment in patients with ChronIc Total OccluSION Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators Asan Medical
More informationΣεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική
ΕΛΛΗΝΙΚΗΚΑΡΔΙΟΛΟΓΙΚΗΕΤΑΙΡΕΙΑ Σεμινάριο Ομάδων Εργασίας 2011 Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική GUIDELINES ON MYOCARDIAL
More informationMedical Rx vs PCI vs CABG
Medical Rx vs PCI vs CABG S. Hinan Ahmed, MD Associate Professor: Cardiology and Cardiothoracic Surgery Program Director: Interventional Fellowship Program Assoc Editor: Cath and Cardiovasc Intervention
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationPCI for Stable Ischemic Heart Disease: What Happened in the Last Week?
PCI for Stable Ischemic Heart Disease: What Happened in the Last Week? Ajay J. Kirtane, MD, SM Center for Interventional Vascular Therapy Columbia University Medical Center / NewYork Presbyterian Hospital
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationESC CONGRESS 2010 Stockholm, august 28 september 1, 2010
ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010 CORONARY ARTERY DISEASE AND NUCLEAR IMAGING: AN UPDATE PERFUSION SCINTIGRAPHY IN HIGH-RISK ASYMPTOMATIC PATIENTS Pasquale Perrone Filardi Federico
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More informationPractical Office Management of Stable Angina
Practical Office Management of Stable Angina All you need to know about it in 30 minutes Andy Ignaszewski MD FRCPC Head, Division of Cardiology PHC Physician Director, PHC Heart Centre Clinical Professor,
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationStable Angina. Conservative Vs Intervention
Stable Angina Chittagong Medical College Hospital Conservative Vs Intervention DR MA SATTAR Associate Professor (Medicine) Chittagong Medical College, Bangladesh Background Coronary artery disease (CAD)
More informationCombining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging
Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging Daniel S. Berman, MD Director, Cardiac Imaging Cedars-Sinai Heart Institute Professor of Medicine and Imaging Cedars-Sinai
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationFFR-CT Not Ready for Primetime
FFR-CT Not Ready for Primetime Leslee J. Shaw, PhD, MASNC, FACC, FAHA, FSCCT R. Bruce Logue Professor of Medicine Co-Director, Emory Clinical CV Research Institute Emory University School of Medicine Atlanta,
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationClinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition
Clinical Case Management of ACS Based on ACC/AHA & ESC Guidelines Dr Badri Paudel Mr M 75M Poorly controlled diabetic Smoker Presented on Sat 7pm Intense burning in the retrosternal area Clinical Case
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationManagement of cardiovascular disease - coronary interventions -
Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationControversies in Coronary Revascularization. Atlanta CCU April 15, 2016
Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationRevascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability
Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability 22nd Annual Heart Failure 2018: an Update on Therapy April 2018 Eric J. Velazquez, MD, FACP, FACC, FASE,
More informationPerioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease
2012 대한춘계심장학회 Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease 울산의대울산대학병원심장내과이상곤 ECG CLASS IIb 1. Preoperative resting 12-lead ECG may be reasonable in patients with
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationCardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology
Cardiac evaluation for the noncardiac patient Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Objectives! Review ACC / AHA guidelines as updated for 2009! Discuss new recommendations
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More information2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?
Evolving Role of Coronary CTA in Primary Cardiovascular Disease Prevention: Are We There Yet? Ron Blankstein, M.D., F.A.C.C. Co-Director, Cardiovascular Imaging Training Program Associate Physician, Preventive
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationStable Angina: Indication for revascularization and best medical therapy
Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationCurrent and Future Imaging Trends in Risk Stratification for CAD
Current and Future Imaging Trends in Risk Stratification for CAD Brian P. Griffin, MD FACC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Disclosures: None Introduction
More informationJMSCR Vol 07 Issue 01 Page January 2018
www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.109 Short Term Outcome in a Severe Coronary Artery Disease with
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationBetter CABGs vs Better PCI Devices
CABG vs PCI 2017 Multivessel Coronary Disease Better CABGs vs Better PCI Devices ACC New York, Dec 8, 2017 No Disclosures CABG vs PCI 2017 Stable Multivessel Coronary Disease 1. Are These The two Critical
More informationCoronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art
Coronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art Harisios Boudoulas, MD, Dr, Dr. Hon. Professor, Honorary Professor, Academician Development of Coronary Artery
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationFractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center
Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude
More informationReconciling the Results of the Randomized Trials
Management of Stable Angina in Multivessel Disease: Reconciling the Results of the Randomized Trials Eric A. Cohen MD, FRCPC Schulich Heart Centre Sunnybrook Health Sciences Centre Toronto ON ACC Rockies
More informationDavid A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio
1 STABLE ISCHEMIC HEART DISEASE: A NON-INVASIVE CARDIOLOGIST S PERSECTIVE 2018 Cardiovascular Course for Trainees and Early Career Physicians APRIL 20, 2018 David A. Orsinelli, MD, FACC, FASE Professor,
More informationCLINICAL CONSEQUENCES OF THE
CLINICAL CONSEQUENCES OF THE FAME STUDY TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands GUIDELINES ESC SEPTEMBER 2010 FFR UPGRADED TO LEVEL
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationRevascularization In HFrEF: Are We Close To The Truth. Ali Almasood
Revascularization In HFrEF: Are We Close To The Truth Ali Almasood HF epidemic 1-2% of the population have HF At least one-half have heart failure with reduced ejection fraction (HF- REF) The most common
More informationSHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?
SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationTreatment of Stable Coronary Artery Disease Pharmacotherapy
Treatment of Stable Coronary Artery Disease Pharmacotherapy José López-Sendón Hospital Universitario La Paz. Madrid. Spain Conflict of interest: I will discuss off label use and/or investigational use
More informationAdvances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline
Advances in Cardiovascular Diagnosis and Therapy Firas Zahr, MD Assistant Professor of Medicine Interventional Cardiology University Of Iowa No disclosure or conflicts Outline What is new with revascularization?
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More information